Pediatric Neurology
Volume 36, Issue 2 , Pages 81-83 , February 2007

Safety of Rapid Intravenous Valproate Infusion in Pediatric Patients

  • Lawrence D. Morton, MD

      Affiliations

    • Division of Child Neurology, Virginia Commonwealth University, Richmond, Virginia
    • Corresponding Author InformationCommunications should be addressed to: Dr. Morton; Children’s Pavilion; PO Box 980211; 1001 East Marshall Street; Richmond, VA 23298-0211.
    • ,
  • Kathryn A. O’Hara, RN

      Affiliations

    • Division of Child Neurology, Virginia Commonwealth University, Richmond, Virginia
    • ,
  • B. Patrick Coots, PharmD

      Affiliations

    • Department of Pharmacy, Virginia Commonwealth University, Richmond, Virginia.
    • ,
  • John M. Pellock, MD

      Affiliations

    • Division of Child Neurology, Virginia Commonwealth University, Richmond, Virginia

Received 28 June 2006 ,Accepted 13 November 2006.

References 

  1. Depacon. North Chicago, IL: Abbott Laboratories; 2003;[package insert]
  2. Venkataraman V, Wheless JW. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res. 1999;35:147–153
  3. Limdi NA, Faught E. The safety of rapid valproic acid infusion. Epilepsia. 2000;41:1342–1345
  4. Naritoku DK, Mueed S. Intravenous loading of valproate for epilepsy. Clin Neuropharmacol. 1999;22:102–106
  5. Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology. 2000;55:722–724
  6. Ramsay RE, Cantrell D, Collins SD, et al. Safety and tolerance of rapidly infused Depacon: a randomized trial in subjects with epilepsy. Epilepsy Res. 2003;52:189–201
  7. Birnbaum AK, Kriel RL, Norberg SK, et al. Rapid infusion of sodium valproate in acutely ill children. Pediatr Neurol. 2003;28:300–303
  8. Yu K-T, Mills S, Thompson N, Cunanan C. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia. 2003;44:724–726
  9. Boggs JG, Preis K. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit. Epilepsia. 2005;46:949–951
  10. Devinsky O, Leppik I, Willmore LJ, et al. Safety of intravenous valproate. Ann Neurol. 1995;38:670–674
  11. Cloyd JC, Dutta S, Cao G, et al., Group TDS Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res. 2003;53:19–27
  12. Perucca E. Pharmacologic and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16:695–714
  13. Aldenkamp A, Vigevano F, Arzimanoglou A, Covanis A. Role of valproate across the ages: treatment of epilepsy in children. Acta Neurol Scand. 2006;114(Suppl 184):1–13

PII: S0887-8994(06)00674-6

doi: 10.1016/j.pediatrneurol.2006.11.003

Pediatric Neurology
Volume 36, Issue 2 , Pages 81-83 , February 2007

Article Tools